Swiss-based MedAlliance, known for its pioneering Drug-Eluting Balloon technology, has been acquired by Cordis in a significant deal worth $1.13 billion.

This acquisition positions Cordis to enhance the global availability of MedAlliance's innovative medical solutions, particularly its Drug-Eluting Balloon designed for coronary and peripheral artery diseases.

With manufacturing in the US and R&D hubs in Switzerland and Singapore, MedAlliance specializes in advanced drug-device combination products, promising advancements in healthcare.

According to Amit Bohora, an early MedAlliance partner, this collaboration signifies a monumental stride in medical innovation, reinforcing the commitment to addressing worldwide healthcare challenges. Bohora emphasized the potential for Cordis's global influence to further MedAlliance's innovation endeavors.

MedAlliance's groundbreaking Sirolimus Drug Eluting Balloon, Selution SLR, has been praised for its effective medication delivery without residual elements, transforming stentless PCI angioplasty procedures.

Bohora highlighted India's significance in this context, citing the burgeoning medical technology landscape and the massive potential in the Indian medical device industry, projected to reach Rs 3.6 lakh crore by 2030 from its current Rs 90,000 crore valuation.

This underlines the substantial opportunities for innovation and growth in this sector, especially given the sizable diabetic patient population.

The acquisition marks a strategic move by Cordis to leverage MedAlliance's advanced technology, poised to shape the future of medical intervention and enhance global healthcare accessibility.